ES2729111T3 - Método para la preparación de adyuvante de hidroxifosfato de aluminio - Google Patents

Método para la preparación de adyuvante de hidroxifosfato de aluminio Download PDF

Info

Publication number
ES2729111T3
ES2729111T3 ES12851733T ES12851733T ES2729111T3 ES 2729111 T3 ES2729111 T3 ES 2729111T3 ES 12851733 T ES12851733 T ES 12851733T ES 12851733 T ES12851733 T ES 12851733T ES 2729111 T3 ES2729111 T3 ES 2729111T3
Authority
ES
Spain
Prior art keywords
aluminum
phosphate
solution
buffer
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12851733T
Other languages
English (en)
Spanish (es)
Inventor
David Thiriot
Patrick Ahl
Jayme Cannon
Gabriel Lobel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2729111T3 publication Critical patent/ES2729111T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00—Phosphorus; Compounds thereof
    • C01B25/16—Oxyacids of phosphorus; Salts thereof
    • C01B25/26—Phosphates
    • C01B25/36—Aluminium phosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ES12851733T 2011-11-23 2012-11-19 Método para la preparación de adyuvante de hidroxifosfato de aluminio Active ES2729111T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563213P 2011-11-23 2011-11-23
PCT/US2012/065741 WO2013078102A1 (en) 2011-11-23 2012-11-19 Method for preparation of aluminum hydroxyphosphate adjuvant

Publications (1)

Publication Number Publication Date
ES2729111T3 true ES2729111T3 (es) 2019-10-30

Family

ID=48470220

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12851733T Active ES2729111T3 (es) 2011-11-23 2012-11-19 Método para la preparación de adyuvante de hidroxifosfato de aluminio

Country Status (6)

Country Link
US (1) US9573811B2 (cg-RX-API-DMAC7.html)
EP (1) EP2782594B1 (cg-RX-API-DMAC7.html)
KR (1) KR102032002B1 (cg-RX-API-DMAC7.html)
ES (1) ES2729111T3 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN03391A (cg-RX-API-DMAC7.html)
WO (1) WO2013078102A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100130T1 (it) * 2015-06-12 2021-05-07 Biological E Ltd Metodo per la preparazione di gel di fosfato di alluminio per applicazione in formulazioni vaccinali
US20190314486A1 (en) 2016-10-21 2019-10-17 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
JP2021501144A (ja) * 2017-10-25 2021-01-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アジュバントワクチン
US11566051B2 (en) 2018-01-29 2023-01-31 Merck Sharp & Dohme Llc Stabilized RSV F proteins and uses thereof
EP3556728A1 (en) * 2018-04-16 2019-10-23 Croda Denmark A/S Organically modified mineral micro-particles, methods of preparing the same and uses thereof
JP6677428B1 (ja) * 2018-05-23 2020-04-08 一般財団法人阪大微生物病研究会 リン酸アルミニウム化合物
WO2020081933A1 (en) * 2018-10-19 2020-04-23 Translate Bio, Inc. Pumpless encapsulation of messenger rna
CN111803627B (zh) 2019-04-11 2023-01-03 厦门万泰沧海生物技术有限公司 唑来膦酸锌微纳米颗粒佐剂的制备及作为疫苗佐剂的用途
US12419951B2 (en) 2019-05-30 2025-09-23 Xiamen University Preparation of zinc risedronate micro/nano adjuvant and use thereof as vaccine adjuvant
CN113666404B (zh) * 2021-09-23 2023-07-28 北京智飞绿竹生物制药有限公司 一种适合规模化生产的高浓度纳米级氢氧化铝佐剂配制方法
KR20230047827A (ko) * 2021-10-01 2023-04-10 에스케이바이오사이언스(주) 향상된 효능을 갖는 알루미늄계 애주번트를 제조하는 방법
KR20240147612A (ko) * 2023-03-31 2024-10-08 에스케이바이오사이언스(주) 향상된 효능을 갖는 알루미늄계 애주번트를 제조하는 방법
US20240376157A1 (en) 2023-05-08 2024-11-14 Merck Sharp & Dohme Llc Polynucleotides encoding norovirus vp1 antigens and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016252A (en) 1972-04-06 1977-04-05 Institut Pasteur Calcium phosphate gel for adsorbing vaccines
FR2181426B1 (cg-RX-API-DMAC7.html) 1972-04-06 1974-12-20 Pasteur Institut
US8540955B2 (en) * 2007-07-10 2013-09-24 Wyeth Llc Process for producing aluminum phosphate
EP2430040A1 (en) 2009-05-11 2012-03-21 Novartis AG Antigen purification process for pertactin antigen
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition

Also Published As

Publication number Publication date
US9573811B2 (en) 2017-02-21
KR20140100530A (ko) 2014-08-14
KR102032002B1 (ko) 2019-10-14
WO2013078102A1 (en) 2013-05-30
IN2014CN03391A (cg-RX-API-DMAC7.html) 2015-07-03
US20140314653A1 (en) 2014-10-23
EP2782594A1 (en) 2014-10-01
EP2782594B1 (en) 2019-04-17
EP2782594A4 (en) 2015-07-29

Similar Documents

Publication Publication Date Title
ES2729111T3 (es) Método para la preparación de adyuvante de hidroxifosfato de aluminio
ES2650740T3 (es) Composición de vacuna con unas nanopartículas de hidróxido de aluminio
CN107595771A (zh) 注射用缓释制剂
ES2634699T3 (es) Métodos para preparar composiciones nanocristalinas usando acústica enfocada
EP3062900A1 (en) Drying techniques for microfluidic and other systems
ES3025099T3 (en) Apparatus and method for mixing small liquid volumes, and use of the apparatus
US8697133B2 (en) Slow release compositions
US20250152622A1 (en) Aluminum-manganese composite nanocrystal, and preparation method therefor and use thereof
BR112020001051A2 (pt) fabricação contínua de conjugados de medicamentos com molécula de orientação.
WO2023134783A2 (zh) 一种铝纳米晶递送系统及其结合疫苗抗原分子自组装颗粒佐剂疫苗
CN202168952U (zh) 一种全自动无菌配药设备
BR112020001058A2 (pt) remoção de medicamento dissociado após acoplamento de conjugado a anticorpo e medicamento
ES2862379T3 (es) Método para la preparación de gel de fosfato de aluminio para su aplicación en formulaciones de vacuna
CN112295476A (zh) 静态微混合芯片装置、磷酸铝佐剂的制备方法及其应用
CN117208948B (zh) 一种氢氧化铝佐剂的制备方法及其应用
BR112017026816B1 (pt) Processo para a preparação de gel de fosfato de alumínio
CN117815383A (zh) 一种亚微米至纳米级粒径可调氢氧化铝佐剂的制备方法
JP2024119170A (ja) 医薬組成物、医薬組成物の製造方法および医薬組成物の製造装置
EA042612B1 (ru) Вакцинная композиция и способ ее получения
WO2025244961A1 (en) Processes for making stable nanoemulsion adjuvants
CN115209980A (zh) 用于保持溶液均质性的摇动平台
WO2010125360A1 (en) Protein crystallisation
WO2011145914A1 (es) La lidocaína como transformadora y productora de complejos de fármacos trasformados aplicados en nanodosis mediante implantes por inyección como dispositivos de liberación prolongada